Describing the diagnosis and clinical classification of Pulmonary Hypertension, according to the 7th World Symposium and recent 2022 ERS/ESC guideline updates, as well as the treatment algorithms with respect to PAH-specific therapies, including new therapeutics approved since the 16th NCRTPH Symposium.

Reviewing the current treatment algorithms for PAH presented at the 7th World Symposium, with particular emphasis on the challenges of determining therapeutic approach in nuanced patient situations and with the availability of sotatercept as a treatment option. 

Recognizing the current data with regard to incidence of PAH in CTD populations and understanding the available clinical trial data for CTD patients treated with PAH therapies in phase 3 studies. Furthermore, understanding the importance of differential clinical presentations and outcomes for CTD PAH patients relative to other PAH subtypes.

Describing the varying presentations of combined pre and post capillary pulmonary hypertension as well as the diagnostic and treatment challenges each may present to the clinician. Discussing what data is available with regard to treating this patient population and what trials are underway for the application of PAH therapies in these patients. 

Discussing a series of cased based presentations, gain a deeper understanding and recognition of nuanced clinical situations in which the role and management of PAH therapy can be challenging to determine and navigate. Learning approaches to manage these patient scenarios from PH center expert clinicians.

Describing the development and evolution of PAH risk calculators, including their integration into the treatment algorithms engineered by the ERS/ESC 2022 guidelines and the 7th World Symposium. Specifically, understanding where further development of these tools is needed, particularly the inclusion of hemodynamics and advanced cardiac imaging to improve their prognostic capabilities.

Identifying the unique situations of pulmonary hypertension complicating end stage renal disease and hepatic disease, and how PH can impact the operative strategies and risks around renal and hepatic transplant surgery.

Describing the diagnosis, classification and management of PH in the setting of lung disease, particularly COPD and ILD, and the evidence base (or lack thereof) for treating PH directly in these populations.